Admir Öztürk

Mr. Admir Öztürk


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
BKBerkay Kilic
Berkay Kilic
AÖAdmir Öztürk
Admir Öztürk
SKSejla Karup
Sejla Karup
EHErvanur Hacioglu
Ervanur Hacioglu
SUSerdal Ugurlu
Serdal Ugurlu
Objectives: Still’s disease is a rare autoinflammatory disorder characterized by systemic inflammation, fever, rash and arthritis. The term ‘Still’s disease’ covers the paediatric subtype systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), which affects adults. Biologic drugs, including the anti-IL-1 agents anakinra, canakinumab and rilonacept and the IL-6 antagonist tocilizumab, are used in the management of Still’s disease. Methods: We conducted a systematic review and network meta-analysis of randomized controlled trials, and the study protocol was registered in PROSPERO (CRD42023450442). MEDLINE, EMBASE and CENTRAL were screened from inception until 17 September 2023. We included patients with Still’s disease who received placebo or biologic drugs: anakinra, canakinumab, rilonacept or tocilizumab. The primary efficacy and safety outcomes were achievement of ACR50 response and occurrence of serious adverse events, respectively. The interventions were ranked using rankograms and SUCRA values. Results: Nine trials with 430 patients were included. All biologic drugs were associated with greater odds of ACR50 response compared with placebo. There was no statistically significant association between biologic drugs and serious adverse events. The multivariate meta-analysis found no difference between biologic drugs. As per SUCRA rankings, anakinra was the most effective and safe option with respect to ACR50 response and occurrence of serious adverse events. Conclusion: This is the first systematic review and meta-analysis to assess the efficacy and safety of biologic drugs in paediatric and adult patients with Still’s disease. Biologic drugs were effective in achieving ACR response and demonstrated a low adverse event profile in the management of Still’s disease.

16 September 2024 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
BKBerkay Kilic
Berkay Kilic
KPKerem Parlar
Kerem Parlar
SKSejla Karup
Sejla Karup
AÖAdmir Öztürk
Admir Öztürk
KKKardelen Karaahmetli
Kardelen Karaahmetli
SUSerdal Ugurlu
Serdal Ugurlu

21 March 2026 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
MGMEHMET HAMZA GULTEKIN
MEHMET HAMZA GULTEKIN
KŞKadir Can Şahin
Kadir Can Şahin
AÖAdmir Öztürk
Admir Öztürk
FIFeyyaz Irmak
Feyyaz Irmak
BOBulent Onal
Bulent Onal
Context: Holmium laser enucleation of the prostate (HoLEP) is a guideline-endorsed, size-independent surgical standard for benign prostatic hyperplasia (BPH). However, conventional HoLEP is frequently associated with loss of antegrade ejaculation (AE), an outcome of increasing importance for sexually active patients. Anatomically informed modifications aimed at preserving peri-ejaculatory structures have been proposed, yet the evidence supporting antegrade ejaculation-preserving HoLEP (EP-HoLEP) remains fragmented. Objective: To systematically review and synthesize the contemporary evidence on ejaculation-preserving HoLEP techniques, focusing on ejaculatory outcomes, urinary function, and surgical safety. Evidence Acquisition: A systematic literature search of PubMed and Embase was conducted in accordance with the PRISMA 2020 guidelines to identify studies evaluating EP-HoLEP techniques published through December 2025. Randomized controlled trials, prospective comparative studies, and retrospective cohorts reporting ejaculatory outcomes were eligible. Risk of bias was assessed using RoB 2, ROBINS-I, and MINORS tools as appropriate. Evidence Synthesis: Ten studies encompassing 1,675 patients were included, comprising three randomized controlled trials, four non-randomized comparative studies, and three single-arm case series. EP-HoLEP techniques were categorized as ejaculatory hood–sparing, mucosal and sphincter-sparing (including modified two-lobe and Double-n techniques), and selective median-lobe enucleation. Hood-sparing approaches alone demonstrated limited efficacy in preserving AE. In contrast, techniques that preserved peri-verumontanum tissue, anterior urethral mucosa, and bladder-neck fibers consistently achieved higher AE preservation rates, reaching 70–85% in selected cohorts. Selective median-lobe enucleation yielded the highest AE preservation in anatomically favourable patients but was associated with less pronounced symptom relief in some series. Across studies, improvements in International Prostate Symptom Score and maximum urinary flow rate were comparable to standard HoLEP, with no consistent increase in perioperative complications, although some techniques required longer operative times. Overall methodological quality was moderate, with residual confounding and heterogeneity limiting direct comparison. Conclusions: EP-HoLEP techniques can substantially improve rates of antegrade ejaculation without compromising short-term urinary outcomes in appropriately selected patients. Effective preservation appears to depend on anatomically informed modification of the enucleation plane rather than superficial tissue sparing alone. EP-HoLEP represents a spectrum of techniques rather than a single standardized approach, and potential trade-offs related to operative complexity and durability should be discussed during patient counselling. High-quality, standardized prospective studies are needed to define optimal techniques and long-term outcomes. Patient Summary: Modified HoLEP techniques that preserve key anatomical structures involved in ejaculation may help sexually active men maintain normal ejaculation while still achieving effective relief of urinary symptoms from prostate enlargement.

21 January 2025 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
AÖAdmir Öztürk
Admir Öztürk
LYLara Yagci
Lara Yagci
SUSerdal Ugurlu
Serdal Ugurlu
Deficiency of adenosine deaminase 2 (DADA2) has been a challenging diagnosis to make since it was first described in 2014. The disease represents a wide range of phenotypes. Therefore, it may present with various clinical patterns. Throughout the years, several difficult-to-diagnose cases of DADA2 were reported in the literature. Although several studies and reviews were published regarding different phenotypes and manifestations of DADA2, a review of challenging cases with diverse combinations of DADA2 manifestations was needed to integrate the knowledge from the literature into the clinical practice. Immunological, hematologic, autoinflammatory, and adult-onset polyarteritis-nodosa patterns were reported in the literature as cases challenging to diagnose. In this review, we aim to summarize the challenging case reports from the literature, provide an algorithmic approach for these kinds of presentations, and share our perspective and recommendations on the topic. Diagnosing DADA2 on time is a vital issue for preventing fatal and debilitating vascular events with anti-TNF-alpha therapy. Thus, early testing for DADA2 in suspected cases is recommended. Family history and genetic testing of the patient and the first-degree relatives are essential for accurate diagnosis. Thorough systemic examination and imaging might help detect clinically silent findings of vasculitis. Enzymatic activity of ADA2, when available, is also a key diagnostic tool that complements genetic testing and clinical evaluation.

30 July 2025 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
EDEmine Şebnem Durmaz
Emine Şebnem Durmaz
GIGünDüz İnCesu
GünDüz İnCesu
TETolga Kaan Erden
Tolga Kaan Erden
LYLara Yağcı
Lara Yağcı
AÖAdmir Öztürk
Admir Öztürk
EDEser Durmaz
Eser Durmaz
Objective: Coronary computed tomography angiography (CCTA) is one of the most used non-invasive imaging modalities for assessing obstructive coronary artery disease (CAD). Beyond the coronary arteries, CCTA also evaluates the structures adjacent to the heart and commonly diagnoses noncardiac pathologies. This study aimed to investigate the incidence and clinical significance of noncardiac findings in patients who underwent CCTA with the suspicion of obstructive CAD. Methods: Patients who underwent CCTA between 2021 and 2024 were retrospectively included. Patients with prior diagnoses of noncardiac pathologies were excluded from the study. Noncardiac findings were assessed according to their clinical significance and/or relation to the patient’s complaints. Results: A total of 2208 patients were screened, and 2103 patients were included after excluding ineligible patients. Among 2103 CCTA imaging, 615 noncardiac findings were detected in 586 patients (27.8% of the study population). In 88 patients, noncardiac findings were possibly related to patient complaints, and only 5 patients among 88 patients demonstrated obstructive CAD. Hence, in 83 patients, noncardiac findings are considered the cause of complaints. Fifty-six findings were thought to be clinically significant and underwent further work-up. Among 56 patients, 3 patients were diagnosed with lung cancer, 1 patient with lymphoma, 1 patient with neuroendocrine carcinoma, 1 patient with peripheral nerve sheath tumor, and 1 patient with sarcoidosis. Conclusion: The results demonstrated that CCTA is a feasible technique not only for assessing CAD but also for helping to differentially diagnose chest pain. In addition, incidental findings might be clinically significant and lead to early diagnosis of life-threatening conditions. Cite this article as: Durmaz EŞ, İncesu G, Erden TK, et al. Incidental noncardiac findings at coronary computed tomographyangiography. Cerrahpaşa Med J 2025, 49, 0039, doi:10.5152/cjm.2025.25039.

17 February 2026 in Rheumatology
Verified
Journal Article
Closed access
AÖAdmir Öztürk
Admir Öztürk
BKBerkay Kilic
Berkay Kilic
MKMurad Kucur
Murad Kucur
LYLara Yagci
Lara Yagci
SUSerdal Ugurlu
Serdal Ugurlu
Objectives: FMF is a genetic autoinflammatory condition marked by recurrent fever and serositis. Colchicine is the mainstay treatment. However, 5% to 10% of patients exhibit colchicine resistance, requiring alternative therapies. Early identification of resistance is vital. While some scoring systems exist for paediatric FMF, artificial intelligence’s (AI’s) potential to predict colchicine resistance in adult patients with FMF has not been systematically explored. This study aimed to utilize machine-learning (ML) and deep-learning (DL) algorithms to predict colchicine resistance in adult patients with FMF. Methods: We retrospectively analysed data from 965 adult patients with FMF diagnosed according to the Tel Hashomer criteria with genetically confirmed FMF and at least 1 year of follow-up. Data for features including mutation type, specific MEFV mutations, presence of arthritis, arthralgia, oligoarthritis, age at diagnosis, and attack frequency were selected. The data were split 80:20 for training and testing. We developed a logistic regression model and a fully connected neural network. Model performance was assessed using the Area Under the Curve (AUC) of the receiver operating characteristic (ROC) curve and other performance metrics. Results: Both the logistic-regression and DL models achieved an AUC of 0.79. Statistically significant differences between colchicine-resistant and non-resistant groups were found for the homozygous mutation type (P = 0.0005), presence of recurrent arthritis (P = 0.0033), presence of chronic arthralgia (P = 0.0286), age of diagnosis (P = 0.0022), and frequency of attacks (P = 0.0436). Conclusion: Our findings suggest that AI-based algorithms, particularly DL models, show significant potential in predicting colchicine resistance in adult patients with FMF. These models could assist in early treatment decision-making, facilitating tailored therapeutic strategies for resistant patients.